AXERT Patient Analyzer

Ask Her Why She Waits

Asking your patients a few key questions could make all the difference in the acute migraine therapy you select. For example, a patient who experiences migraines during the day may be more inclined to delay treatment due to concerns about feeling sleepy or tired after taking her migraine medication. So ask her when she typically experiences her migraines, then ask her why she waits. Use this patient evaluator to see if AXERT may help you provide an effective option that offers relief without many of the side effects that could impact her day.

Use the drop-down menus to select the appropriate information for your patient, then click ANALYZE to see whether he or she is a candidate for migraine therapy.

Indication
AXERT tablets are indicated for the acute treatment of migraine with or without aura in adults.
AXERT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Safety and effectiveness of AXERT have not been established for cluster headache, which is present in an older, predominantly male population.

IMPORTANT SAFETY INFORMATION
AXERT tablets should be used only when a clear diagnosis of migraine has been established. AXERT, like other triptans, has been associated with coronary vasospasm and therefore should not be given to patients with ischemic heart disease or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm (including Prinzmetal's variant angina), or other significant underlying cardiovascular disease. AXERT, like other triptans in this class, should not be given to patients in whom unrecognized coronary artery disease (CAD) is predicted by risk factors (family history, high cholesterol, high blood pressure, diabetes, or obesity). Because AXERT may increase blood pressure, it should not be given to patients with uncontrolled hypertension.

The development of a potentially life-threatening serotonin syndrome may occur with triptans, including AXERT treatment, particularly when combined with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). If combined treatment with AXERT and an antidepressant is clinically warranted, patients should be closely observed for signs and symptoms of the serotonin syndrome such as mental status changes, hyperthermia, diaphoresis, labile blood pressure, tachycardia, hyperreflexia, incoordination and/or gastrointestinal symptoms, especially during treatment initiation and dosage escalation. Patients with the serotonin syndrome require immediate medical attention.

The most common side effects are nausea, sleepiness, paresthesia, headache and dry mouth.

Ask your healthcare professional about the side effects and other important considerations before taking AXERT.

For more detailed information, please see full Prescribing Information.

Celexa and Lexapro are registered trademarks of Forest Laboratories.
Paxil is a registered trademark of Glaxo Smith Kline.
Symbyax, Prozac/Sarafem and Cymbalta are registered trademarks of Eli Lilly.
Zoloft is a registered trademark of Pfizer.
Luvox is a registered trademark of Solvay.
Effexor is a registered trademark of Wyeth.

©Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2003-2009. All rights reserved. Licensed from Almirall Prodesfarma. Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy.

Ortho-McNeil Neurologics, division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. publishes this site and is solely responsible for its contents. The TOPAMAX360.com, RAZADYNEER360.com, TOPAMAXEPILEPSY360.com, and AXERT360.com sites are directly affiliated with OMN360.com and the same terms of use apply across all sites.

Capitalized product names are trademarks of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

This information is intended for use by our customers, patients, and healthcare professionals in the United States only. Ortho-McNeil-Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States.